ArticleFrontiers in oncology2026
Case Report: Solitary right thigh skin metastasis of bladder cancer misdiagnosed as erysipelas with literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous metastasis from bladder carcinoma is an uncommon clinical manifestation and may be misdiagnosed as a benign inflammatory dermatosis, such as erysipelas, causing diagnostic delay and missed opportunities for timely systemic treatment. Case presentation: We report a case of a 70-year-old man with a history of muscle-invasive bladder carcinoma treated with radical cystectomy and bilateral cutaneous ureterostomies, who presented 6 years later with a maculopapular rash on his right thigh. The lesion was initially misdiagnosed and treated as erysipelas for over 2 months without improvement. A subsequent skin biopsy confirmed metastatic urothelial carcinoma, with immunohistochemistry positive for GATA-3, CK7, and CK20. The tumor also exhibited Human epidermal growth factor receptor 2 (HER2) (2+) expression and high Programmed death-ligand 1 (PD-L1) (Combined Positive Score (CPS) = 20). Based on prior intolerance to cisplatin-based chemotherapy and the tumor biomarker profile, combination therapy with disitamab vedotin and tislelizumab was initiated. This regimen led to complete resolution of pain by cycle 6, and achieved complete clinical and radiological remission of the skin metastasis after 18 cycles of treatment. However, the patient later developed grade 3 immune-related adrenal insufficiency, necessitating hormone replacement and permanent discontinuation of immunotherapy. Conclusion: Persistent inflammatory-appearing skin lesions in patients with a history of bladder cancer should prompt early biopsy, particularly when they are refractory to antibiotic therapy. Molecular profiling may help identify actionable targets and guide systemic treatment. This case highlights the diagnostic challenge of erysipelas-like cutaneous metastasis and suggests the potential value of biomarker-guided HER2-directed antibody-drug conjugate plus Programmed cell death protein 1 (PD-1) inhibitor therapy in selected patients with metastatic urothelial carcinoma, while emphasizing the need for careful monitoring of immune-related toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.